Plantamajoside attenuates cardiac fibrosis via inhibiting AGEs activated-RAGE/autophagy/EndMT pathway

Lu Zhang1,2,3,4, Yi-Ning Guo1,2,3,4, Jing Liu2,3

  • 1Dongguan Hospital, Guangzhou University of Chinese Medicine, Dongguan, China.

Insights

Plantamajoside (PMS) combats cardiac fibrosis in chronic heart failure (CHF) by blocking the AGEs/RAGE/autophagy/EndMT pathway. This natural compound offers a potential therapeutic strategy for heart conditions.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Molecular Biology

Background:

  • Advanced glycation end products (AGEs) signal through receptor for AGEs (RAGE), promoting fibrotic diseases.
  • Disrupting the AGE-RAGE interaction is a therapeutic target for chronic heart failure (CHF).
  • Endothelial-to-mesenchymal transition (EndMT) is implicated in cardiac fibrosis, and RAGE activation mediates this process via autophagy.

Purpose of the Study:

  • To investigate the protective role of Plantamajoside (PMS) in CHF.
  • To elucidate the underlying mechanism of PMS action on the AGEs/RAGE/autophagy/EndMT axis.
  • To determine if PMS can attenuate cardiac fibrosis and dysfunction in a mouse model of CHF.

Main Methods:

  • Administered PMS to mice with experimentally induced CHF.
  • Assessed cardiac function, fibrosis, and EndMT markers.
  • Measured autophagy levels and serum AGEs.
  • Investigated PMS binding to RAGE in vitro and its effect on the AGEs-RAGE-autophagy-EndMT pathway.

Main Results:

  • PMS attenuated cardiac fibrosis and dysfunction in CHF mice.
  • PMS suppressed EndMT and reduced autophagy and serum AGEs levels.
  • PMS competitively bound to the V-domain of RAGE, inhibiting the AGEs-induced RAGE-autophagy-EndMT pathway in vitro.

Conclusions:

  • Plantamajoside (PMS) demonstrates anti-fibrotic effects in CHF.
  • PMS acts by competitively inhibiting the AGEs-activated RAGE/autophagy/EndMT pathway.
  • PMS represents a potential therapeutic agent for treating cardiac fibrosis in CHF.